Daniel Whitley, MD
Internal Medicine · Corbin, KYNPI 1043215874
Payments from drug & device makers
Across 419 payments — averaging $14.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$909
- Pfizer$594
- Lilly USA, LLC$497
- AbbVie$495
- Merck$463
- Novartis$355
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,025100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 33 | $909 |
| Pfizer | 55 | $594 |
| Lilly USA, LLC | 58 | $497 |
| AbbVie(2 entities) | 38 | $495 |
| Merck | 41 | $463 |
| Novartis | 24 | $355 |
| Novo Nordisk | 23 | $339 |
| Astellas Pharma US Inc | 19 | $339 |
| Abbott | 17 | $304 |
| Johnson & Johnson | 14 | $227 |
| Boehringer Ingelheim | 19 | $192 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $175 |
| Amarin Pharma, Inc. | 13 | $171 |
| Amgen | 7 | $113 |
| Evoke Pharma, Inc. | 6 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $92 |
| Sumitomo Pharma America, Inc. | 4 | $90 |
| Phathom Pharmaceuticals, Inc. | 1 | $86 |
| Kowa Pharmaceuticals America, Inc. | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 6 | $74 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Exact Sciences | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| GSK | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Livanova USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,025 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 202 | $220,867 |
| EliquisApixaban | 251 | $164,495 |
| OzempicSemaglutide | 92 | $101,118 |
| JardianceEmpagliflozin | 111 | $93,635 |
| FarxigaDapagliflozin Propanediol | 74 | $62,821 |
| TrulicityDulaglutide | 52 | $54,538 |
| LinzessLinaclotide | 71 | $43,468 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 54 | $26,991 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $26,488 |
| RexultiBrexpiprazole | 12 | $25,645 |
| JanuviaSitagliptin Phosphate | 16 | $23,390 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $22,530 |
| EntrestoSacubitril/Valsartan | 23 | $21,280 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $21,036 |
| XareltoRivaroxaban | 31 | $20,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $497 | $275,406254 claims |
| PfizerEliquis, Premarin | $594 | $171,054270 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $909 | $101,606150 claims |
| Novo NordiskOzempic | $339 | $101,11892 claims |
| Boehringer IngelheimJardiance | $192 | $93,635111 claims |
| MerckJanumet Xr, Januvia, Janumet | $463 | $72,911105 claims |
| AbbVieLinzess, Synthroid | $495 | $48,483175 claims |
| GSKShingrix, Trelegy Ellipta, Breo Ellipta | $15 | $42,336142 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $53 | $25,64512 claims |
| NovartisEntresto | $355 | $21,28023 claims |
| Johnson & JohnsonXarelto | $227 | $20,82631 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $92 | $18,26827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Corbin
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.